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CONTEXT: Mutations in CHD7, a gene previously implicated in CHARGE (coloboma,
heart defect, choanal atresia, retardation of growth and/or development, genital
hypoplasia, ear anomalies) syndrome, have been reported in patients presenting with
Kallmann syndrome (KS) or congenital hypogonadotropic hypogonadism (CHH). Most
mutations causing CHARGE syndrome result in premature stop codons and occur de
novo, but the proportion of truncating vs nontruncating mutations in KS and CHH
patients is still unknown. OBJECTIVE: The objective of the study was to determine
the nature, prevalence, mode of transmission, and clinical spectrum of CHD7
mutations in a large series of patients. DESIGN: We studied 209 KS and 94 CHH
patients. These patients had not been diagnosed with CHARGE syndrome according
to the current criteria. We searched for mutations in 16 KS and CHH genes including
CHD7. RESULTS: We found presumably pathogenic mutations in CHD7 in 24 KS
patients but not in CHH patients. Nontruncating mutations (16 missense and a two-
codon duplication) were more prevalent than truncating mutations (three nonsense,
three frame shift, and a splice site), which contrasts with patients presenting with
typical CHARGE syndrome. Thus, the clinical spectrum associated with CHD7
mutations may be partly explained by genotype/phenotype correlations. Eight
patients also had congenital deafness and one had a cleft lip/palate, whereas six had
both. For 10 patients, the presence of diverse features of the CHARGE spectrum in at
least one relative argues against a de novo appearance of the missense mutation, and
this was confirmed by genetic analysis in five families. CONCLUSION: Considering
the large prevalence and clinical spectrum of CHD7 mutations, it will be particularly
relevant to genetic counseling to search for mutations in this gene in KS patients
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